TITLE:
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

CONDITION:
Nausea

INTERVENTION:
MK0869, aprepitant / Duration of Treatment: 3 days

SUMMARY:

      This protocol will study an investigational drug treatment plan against standard therapy in
      the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast
      cancer who are to be treated with up to 4 cycles of non-cisplatin moderately emetogenic
      chemotherapy.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin
             moderately emetogenic chemotherapy.

        Exclusion Criteria:

          -  Patient has a central nervous system malignancy.

          -  Patient will receive radiation to the abdomen or pelvis.
      
